Stock listing

NYSE American:ARMP Armata Pharmaceuticals, Inc. Stock

Home listing (NYSE American) of Armata Pharmaceuticals, Inc.

Follow Armata Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · AMEX:ARMP

$3.03 USD -0.14 (-4.4%)

Close on Nov 20, 2026

Past year -57.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.89 – $3.19 USDNov 20, 2026
Volume
85,641 sharesNov 20, 2026
Market cap
$112.7M USDAt the close on Nov 20, 2026 · price × 37.19M shares outstanding
52-week range
$2.40 – $14.98 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$839,482 USDMedian day 91,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Armata Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:ARMP · Home$3.03 USD-0.14 (-4.4%)85,641$2.92$3.19$2.89$3.17Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:ARMP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.03-0.14-4.4%$2.92$3.19$2.8985,641
$3.17+0.51+19.2%$2.59$3.17$2.5789,167
$2.66-0.33-11.0%$2.95$3.01$2.40238,600
$2.99-0.88-22.7%$3.84$4.13$2.98159,500
$3.87+0.15+4.0%$3.85$3.91$3.6128,600
$3.72-0.17-4.4%$3.85$3.90$3.54105,100
$3.89+0.14+3.7%$3.73$3.89$3.5750,500
$3.75-0.05-1.3%$3.54$3.77$3.4364,000
$3.80+0.29+8.3%$3.52$3.88$3.27101,800
$3.51+0.51+17.0%$3.00$3.51$3.0069,300
$3.00-0.14-4.5%$2.98$3.20$2.9346,400
$3.14+0.05+1.6%$3.12$3.32$3.0764,200
$3.09+0.24+8.4%$2.89$3.10$2.8942,900
$2.85-0.43-13.1%$3.28$3.31$2.8085,900
$3.28+0.03+0.9%$3.39$3.44$3.2046,700
$3.25-0.04-1.2%$3.28$3.40$3.15102,900
$3.29-0.20-5.7%$3.49$3.84$3.2262,100
$3.49+0.04+1.2%$3.40$3.73$3.40104,300
$3.45-0.19-5.2%$3.62$3.70$3.4063,600
$3.64+0.19+5.5%$3.44$3.80$3.44115,600
$3.45+0.39+12.7%$3.04$3.50$3.03107,900
$3.06-0.14-4.4%$3.21$3.21$2.9493,600
$3.20+0.13+4.2%$3.14$3.41$3.1187,300
$3.07-0.30-8.9%$3.33$3.41$3.0788,300
$3.37+0.28+9.1%$3.08$3.42$2.98154,300
$3.09+0.31+11.2%$2.86$3.16$2.83115,700
$2.78-0.32-10.3%$3.06$3.06$2.75125,500
$3.10-0.53-14.6%$3.68$3.68$3.01223,200
$3.630.000.0%$3.65$3.84$3.5645,900
$3.63-0.23-6.0%$3.90$3.95$3.62100,600
$3.86+0.05+1.3%$3.79$3.91$3.5970,300
$3.81-0.04-1.0%$3.83$4.07$3.72103,600
$3.85+0.19+5.2%$3.69$3.93$3.66114,600
$3.66+0.14+4.0%$3.54$3.68$3.5156,600
$3.52+0.21+6.3%$3.40$3.55$3.32124,500
$3.31-0.36-9.8%$3.67$3.78$3.2876,400
$3.67+0.08+2.2%$3.57$3.74$3.53127,000
$3.59-0.19-5.0%$3.74$3.74$3.5291,800
$3.78+0.04+1.1%$3.66$3.85$3.5585,700
$3.74+0.12+3.3%$3.60$3.81$3.56100,800
$3.62-0.02-0.5%$3.70$3.83$3.53144,400
$3.64-0.56-13.3%$4.20$4.30$3.60286,900
$4.20-0.06-1.4%$4.27$4.56$4.14128,300
$4.26+0.08+1.9%$4.24$4.36$4.1082,900
$4.18+0.08+2.0%$4.07$4.40$4.00160,600
$4.10+0.03+0.7%$4.32$4.32$4.09253,300
$4.07-0.33-7.5%$4.40$4.44$3.99307,100
$4.40-1.15-20.7%$5.24$5.35$4.23646,200
$5.55+0.17+3.2%$6.17$6.64$4.734,743,600
$5.38+0.15+2.9%$5.30$5.55$5.2643,600
$5.23-0.18-3.3%$5.39$5.74$5.12115,400
$5.41-0.41-7.0%$5.76$5.79$5.4017,900
$5.82-0.02-0.3%$5.76$5.88$5.5947,400
$5.84+0.32+5.8%$5.49$5.87$5.4848,000
$5.52-0.01-0.2%$5.53$5.62$5.2049,300
$5.53+0.25+4.7%$5.36$5.62$5.2770,100
$5.28-0.23-4.2%$5.51$5.68$5.1946,500
$5.51+0.14+2.6%$5.35$5.52$5.1851,500
$5.37-0.06-1.1%$5.37$5.45$4.9949,700
$5.43-0.02-0.4%$5.42$5.47$4.73270,500
$5.45-0.11-2.0%$5.59$5.59$5.3062,200
$5.56+0.39+7.5%$5.23$5.70$5.2394,290
$5.17+0.07+1.4%$5.10$5.26$4.86267,744
$5.10+0.68+15.4%$4.42$5.10$4.42111,500
$4.42-0.65-12.8%$4.98$5.17$4.12222,100

Splits

4 splits since 2006 · AMEX:ARMP · every price before a split is adjusted for it

DayRatioWhat
1-for-14Consolidation
1-for-10Consolidation
1-for-50Consolidation
1-for-10Consolidation
Ticker
NYSE American:ARMP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Armata Pharmaceuticals, Inc. news

Armata Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 37 in all · newest Nov 12, 2026 · oldest 2024
Decks
24 decks · latest Nov 16, 2026

Where Armata Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:ARMP · Home listing · This pageNYSE AmericanUnited StatesUSD
gettex:TG1NgettexGermanyEUR
Lang & Schwarz:A2PKLCLang & SchwarzGermanyEUR
LS Exchange:A2PKLCLS ExchangeGermanyEUR
BOATS:ARMPBOATSUnited StatesUSD
Tradegate:TG1NTradegateGermanyEUR
Dusseldorf:TG1NDusseldorfGermanyEUR
Frankfurt:TG1NFrankfurtGermanyEUR
Munich:TG1NMunichGermanyEUR
Stuttgart:TG1NStuttgartGermanyEUR

Valuation

EV/sales 45.8× against a median of 11.8×: 6th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$346.0M USD
P/E
Loss
EV/sales
45.8×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
−59.1%
Operating margin
−533.5%
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
0.97

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Armata Pharmaceuticals, Inc. · AMEX:ARMPUS$112.7MUS$346.0Mn/a45.8×n/an/an/an/a0.97
STCube, Inc. · KRX:052020US$117.7MUS$72.01Mn/a13.6×n/a2.6×−338.7%0.0×n/a
PegBio Co., Ltd. Class H · HKEX:2565US$117.2MUS$55.85Mn/an/an/a2.9×n/a0.0×n/a
Curacle Co., Ltd. · KRX:365270US$116.9MUS$99.84Mn/a16.3×n/a3.4×−92.1%0.0×n/a
enGene Therapeutics Inc. · NASDAQ:ENGNUS$116.6M−US$149.7Mn/an/an/a0.5×n/a0.0×1.82
Sinew Pharma, Inc. · TPEX:6634US$114.4MUS$84.23Mn/a59,068×n/a3.6×n/a0.0×n/a
Medigen Biotechnology Corporation · TPEX:3176US$111.8MUS$61.96Mn/a1.6×n/a2.5×−19.9%0.8×n/a
Fate Therapeutics, Inc. · NASDAQ:FATEUS$111.7MUS$47.08Mn/a9.9×n/a0.8×n/a0.6×2.25
OnKure Therapeutics, Inc. · NASDAQ:OKURUS$109.4M−US$53.16Mn/an/an/a0.7×n/a0.0×1.17
Spruce Biosciences, Inc. · NASDAQ:SPRBUS$109.2MUS$41.00Mn/an/an/a1.6×n/a0.3×1.73
NIBEC Co., Ltd. · KRX:138610US$108.0MUS$91.96Mn/a5.5×118×3.0×−0.1%0.0×n/a
Median of the othersUS$113.1MUS$58.90M11.8×118×2.6×−56.0%0.0×1.78

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
17.50 USD · Analysts' mean
EPS, year to Dec 2026
-1.46 · 1 analyst
Revenue, year to Dec 2026
3.3M · 1 analyst

Team and board

Officers

OfficerRole
Deborah BirxChief Executive Officer
David HouseChief Financial Officer
Peter HubbardVice President of Operations
Bani TchekanovaHead of Regulatory Strategy and Operations
Pierre KymeChief Business Officer

Board

DirectorRole
Robin C. KramerChair of Board of Directors
Daniel B. GilmerDirector
Deborah BirxChief Executive Officer
Joseph M. PattiDirector
Jules HaimovitzDirector
Odysseas KostasDirector
Sarah J. SchlesingerDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+4.0%
Q2 2026Aug 12, 2026 · After close+11.8%
Q1 2026May 13, 2026 · After close−7.0%
Q4 2025Mar 19, 2026−1.8%
Q3 2025Nov 12, 2025 · After close−4.6%
Q2 2025Aug 12, 2025 · After close+1.6%
Q1 2025May 14, 2025 · After close+1.4%
Q4 2024Mar 19, 2025 · Before open−2.9%
Q3 2024Nov 13, 2024 · After close−1.5%
Q2 2024Aug 13, 2024 · After close−10.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close−3.5%
Q4 2023Mar 21, 2024 · After close+1.4%
Q3 2023Nov 14, 2023 · After close−19.8%
Q2 2023Aug 14, 2023 · Before open−4.4%
Q1 2023May 11, 2023 · After close−3.9%
Q4 2022Mar 16, 2023 · After close+8.6%
Q3 2022Nov 9, 2022 · After close−8.2%
Q2 2022Aug 11, 2022 · After close−0.7%
Q1 2022May 12, 2022 · After close+3.7%
Q4 2021Mar 17, 2022 · After close+17.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck52 slidesNov 16, 2026
Investor Presentation (September 2026)Investor deck52 slidesSep 14, 2026
IDWeek 2025Conference16 slidesOct 22, 2025
H.C. Wainwright 27th Annual Global Investment Conference (September 2025)Conference29 slidesSep 11, 2025
Investor Presentation (May 2025)Investor deck39 slidesMay 19, 2025
Investor Presentation (December 2024)Investor deck34 slidesDec 19, 2024
Investor Presentation (August 2024)Investor deck30 slidesAug 26, 2024
Investor Presentation (March 2023)Investor deck31 slidesMar 6, 2023
Investor Presentation (January 2022)Investor deck21 slidesJan 5, 2022
Investor Presentation (January 2021)Investor deck23 slidesJan 6, 2021
All 24 decks
DeckKindSlidesDate
Investor Presentation (April 2020)Investor deck27 slidesApr 28, 2020
IPO Roadshow (January 2020)IPO roadshow29 slidesJan 9, 2020
Ladenburg Thalmann 2019 Healthcare ConferenceConference22 slidesSep 24, 2019
Technical Presentation (June 2019)Technical54 slidesJun 26, 2019
Investor Presentation (June 2019)Investor deck20 slidesJun 24, 2019
Investor Presentation (May 2019)Investor deck22 slidesMay 14, 2019
AmpliPhi Biosciences — Merger or Acquisition (January 2019)Merger or acquisition18 slidesJan 7, 2019
AmpliPhi Biosciences — Investor Presentation (September 2018)Investor deck21 slidesSep 5, 2018
AmpliPhi Biosciences — Investor Presentation (May 2018)Investor deck27 slidesMay 15, 2018
AmpliPhi Biosciences — Biotech Showcase Conference 2018Conference25 slidesJan 8, 2018
AmpliPhi Biosciences — Investor Presentation (June 2017)Investor deck23 slidesJun 6, 2017
AmpliPhi Biosciences — IPO Roadshow (May 2017)IPO roadshow28 slidesMay 2, 2017
AmpliPhi Biosciences — Investor Presentation (January 2017)Investor deck24 slidesJan 9, 2017
AmpliPhi Biosciences — Investor Presentation (January 2016)Investor deck19 slidesJan 11, 2016

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue4.90M5.17M4.53M5.51M4.47M823.0K31.0K0115.0K260.0K
Cost of revenue1.53M34.4M972.0K35.0M20.0M14.4M1.35M1.35M374.0K369.0K
Gross profit3.37M-29.3M3.56M-29.5M-15.5M-13.6M-1.35M-1.35M-259.0K-109.0K
Research and development23.7M34.4M33.8M35.0M20.0M14.4M9.82M8.37M2.88M5.68M
Selling, general and administrative12.4M13.2M11.6M7.44M8.28M7.97M9.27M5.70M7.59M8.41M
Operating income-36.6M-42.4M-40.9M-36.9M-23.8M-21.6M-19.8M-17.7M-16.2M-23.4M
Depreciation and amortization1.53M1.32M972.0K892.0K1.17M1.11M1.35M1.35M343.0K338.0K
EBITDA-35.1M-41.1M-39.9M-36.1M-22.7M-20.5M-18.4M-16.3M-15.8M-23.0M
Interest expense16.6M10.7M2.63M064.0K628.0K931.0K1.01M06.00K
Income before tax-173.8M-18.9M-69.0M-36.9K-23.2M-22.2M-19.5M-16.7M-14.1M-19.4M
Income tax-29.0K64.0K634.0K-454.0K-328.0K-1.30M-556.0K
Net income-173.8M-18.9M-69.0M-36.9M-23.2M-22.2M-19.5M-16.7M-12.8M-18.8M
Earnings per share, basic-4.80-0.52-1.91-1.08-0.96-1.35-2.49-3.59-2.01-24.67
Earnings per share, diluted-4.80-0.89-1.91-1.08-0.96-1.35-2.55-3.59-2.18-24.67

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents8.69M9.29M13.5M14.9M10.3M9.65M6.03M9.66M5.13M5.13M
Short-term investments9.65M
Receivables472.0K744.0K3.36M8.53M2.99M561.0K12.0K
Inventory-2.99M-561.0K-619.0K
Current assets10.7M11.3M19.2M27.0M15.0M10.8M6.66M10.4M5.38M6.31M
Property, plant and equipment12.2M13.2M12.6M3.62M2.22M2.05M2.19M3.25M816.0K1.07M
Goodwill3.49M3.49M3.49M3.49M3.49M3.49M3.49M0
Total assets76.9M86.4M98.4M95.8M69.8M39.5M25.5M14.5M11.1M18.2M
Accounts payable921.0K766.0K1.58M1.68M1.14M956.0K547.0K415.0K578.0K1.06M
Current liabilities8.95M48.2M16.5M24.9M4.81M6.71M4.88M2.03M1.97M3.54M
Long-term debt256.9M55.4M82.3M
Total debt288.0M126.5M120.4M48.8M38.0M13.2M2.86M803.0K
Total liabilities295.5M134.5M130.4M59.8M44.4M20.7M10.9M6.85M3.41M8.43M
Shareholders' equity-218.6M-48.0M-32.1M36.1M25.4M18.9M14.6M7.69M24.3M9.72M
Shares outstanding36.4M36.2M36.1M36.1M27.1M18.7M9.92M5.07M9.50M1.65M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-25.8M-37.6M-47.4M-32.5M-23.6M-18.3M-15.6M-10.6M-9.19M-10.6M
Capital spending-542.0K-1.88M-8.14M-2.21M-1.30M-824.0K-224.0K-875.0K-58.0K-279.0K
Free cash flow-26.3M-39.4M-55.6M-34.7M-24.9M-19.1M-15.8M-11.5M-9.25M-10.9M
Cash from investing-542.0K-1.88M-8.13M-2.21M-1.30M-824.0K2.88M8.81M-58.0K-279.0K
Cash from financing25.6M35.0M54.0M44.0M25.5M23.2M8.97M12.5M8.67M7.23M
Dividends paid0-80.0K
Share buybacks-43.0K44.5M26.9M23.1M9.97M12.5M9.49M-173.0K
Change in cash-693.0K-4.47M-1.57M9.32M639.0K4.12M-3.73M-1.81M-579.0K-3.66M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
8-K · Current reportSep 23, 2026Current reportSEC
8-K · Current reportSep 14, 2026Current reportSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
8-K · Current reportJul 20, 2026Current reportSEC
8-K · Current reportJul 20, 2026Management or board changeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
8-K · Current reportJul 13, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
S-8 · Registration statement for employee plansJul 10, 2026Offer documentSEC
8-K/A · Current report, amendedJun 24, 2026Management or board changeSEC
8-K · Current reportJun 23, 2026Current reportSEC
8-K · Current reportJun 16, 2026Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
8-K · Current reportMay 7, 2026Current reportSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 28, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 27, 2026Annual reportSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
8-K · Current reportApr 27, 2026Management or board changeSEC
8-K · Current reportApr 2, 2026Current reportSEC
10-K · Annual reportMar 25, 2026Annual reportSEC
8-K · Current reportMar 25, 2026ResultsSEC
8-K · Current reportMar 19, 2026Current reportSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
8-K · Current reportFeb 23, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 26, 2026Big-stake noticeSEC
8-K · Current reportJan 26, 2026Material contractSEC
8-K · Current reportJan 13, 2026Current reportSEC
8-K · Current reportDec 1, 2025Material contractSEC
424B5 · ProspectusDec 1, 2025Offer documentSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportOct 22, 2025Current reportSEC
8-K · Current reportSep 10, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 25, 2025Other filingsSEC
CORRESP · Letter to the SECAug 20, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 15, 2025Other filingsSEC
S-8 · Registration statement for employee plansAug 13, 2025Offer documentSEC
S-3 · Registration statementAug 13, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
4 · Change in ownershipJul 14, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
8-K · Current reportMay 19, 2025Current reportSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
8-K · Current reportMay 1, 2025Current reportSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedApr 25, 2025Insider tradeSEC
8-K · Current reportApr 2, 2025Current reportSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 12, 2025Big-stake noticeSEC
8-K · Current reportMar 12, 2025Material contractSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
8-K · Current reportDec 19, 2024Current reportSEC
8-K · Current reportDec 4, 2024Management or board changeSEC
8-K · Current reportNov 15, 2024Material contractSEC
SC 13D/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportNov 12, 2024Current reportSEC
8-K · Current reportOct 3, 2024Management or board changeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
8-K · Current reportSep 26, 2024Management or board changeSEC
8-K · Current reportAug 26, 2024Current reportSEC
3 · Initial statement of ownershipAug 19, 2024Insider tradeSEC
8-K · Current reportAug 15, 2024Management or board changeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportJul 25, 2024Management or board changeSEC
3 · Initial statement of ownershipJun 28, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
8-K · Current reportMar 22, 2024Current reportSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMar 4, 2024Big-stake noticeSEC
8-K · Current reportMar 4, 2024Material contractSEC
S-8 · Registration statement for employee plansJan 23, 2024Offer documentSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
S-8 · Registration statement for employee plansNov 15, 2023Offer documentSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
UPLOAD · Letter from the SECNov 13, 2023Other filingsSEC
CORRESP · Letter to the SECNov 7, 2023Other filingsSEC
UPLOAD · Letter from the SECOct 26, 2023Other filingsSEC
3 · Initial statement of ownershipSep 22, 2023Insider tradeSEC
8-K · Current reportSep 20, 2023Management or board changeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
ARS · Annual report to shareholdersAug 3, 2023Annual reportSEC
DEFA14A · Additional proxy materialAug 3, 2023Meeting noticeSEC
DEF 14A · Proxy statementAug 3, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 24, 2023Meeting noticeSEC
8-K · Current reportJul 19, 2023Management or board changeSEC
3 · Initial statement of ownershipJul 19, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJul 11, 2023Big-stake noticeSEC
8-K · Current reportJul 11, 2023Material contractSEC
8-K · Current reportJun 27, 2023ResultsSEC
8-K · Current reportMay 11, 2023ResultsSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
3 · Initial statement of ownershipMay 8, 2023Insider tradeSEC
8-K · Current reportMay 5, 2023Management or board changeSEC
EFFECT · Notice that a registration is effectiveApr 7, 2023Other filingsSEC
424B3 · ProspectusApr 6, 2023Offer documentSEC
CORRESP · Letter to the SECApr 5, 2023Other filingsSEC
S-3/A · Registration statement, amendedMar 28, 2023Offer documentSEC
8-K · Current reportMar 16, 2023ResultsSEC
10-K · Annual reportMar 16, 2023Annual reportSEC
8-K · Current reportMar 6, 2023Current reportSEC
UPLOAD · Letter from the SECFeb 17, 2023Other filingsSEC
S-3 · Registration statementFeb 13, 2023Offer documentSEC
3 · Initial statement of ownershipFeb 7, 2023Insider tradeSEC
4 · Change in ownershipJan 12, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 10, 2023Big-stake noticeSEC
8-K · Current reportJan 10, 2023Material contractSEC
8-K · Current reportDec 19, 2022Management or board changeSEC
8-K · Current reportNov 18, 2022Meeting outcomeSEC
8-K · Current reportNov 9, 2022ResultsSEC
10-Q · Quarterly reportNov 9, 2022Quarterly reportSEC
DEF 14A · Proxy statementOct 17, 2022Meeting noticeSEC
8-K · Current reportSep 20, 2022ResultsSEC
8-K · Current reportAug 11, 2022ResultsSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
EFFECT · Notice that a registration is effectiveJun 1, 2022Other filingsSEC
424B3 · ProspectusMay 31, 2022Offer documentSEC
CORRESP · Letter to the SECMay 26, 2022Other filingsSEC
S-3/A · Registration statement, amendedMay 23, 2022Offer documentSEC
UPLOAD · Letter from the SECMay 19, 2022Other filingsSEC
S-3 · Registration statementMay 13, 2022Offer documentSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
4 · Change in ownershipApr 15, 2022Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 7, 2022Other filingsSEC
424B3 · ProspectusApr 6, 2022Offer documentSEC
CORRESP · Letter to the SECApr 5, 2022Other filingsSEC
4 · Change in ownershipApr 1, 2022Insider tradeSEC
SC 13D/A · Big-stake notice, amendedApr 1, 2022Big-stake noticeSEC
UPLOAD · Letter from the SECApr 1, 2022Other filingsSEC
8-K · Current reportMar 31, 2022Meeting outcomeSEC
S-3 · Registration statementMar 29, 2022Offer documentSEC
8-K · Current reportMar 28, 2022Management or board changeSEC
10-K · Annual reportMar 17, 2022Annual reportSEC
DEF 14A · Proxy statementMar 9, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementFeb 24, 2022Meeting noticeSEC
4 · Change in ownershipFeb 11, 2022Insider tradeSEC
SC 13D/A · Big-stake notice, amendedFeb 11, 2022Big-stake noticeSEC
8-K · Current reportFeb 11, 2022Material contractSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Armata Pharmaceuticals, Inc.’s releases · as of Nov 6, 2026

Common shares
37,192,632
Fully diluted
37,192,632

Fully diluted

LineSharesAs of
Common shares37,192,632Nov 6, 2026

Share count over time

CountShares
Nov 6, 202637,192,632
Nov 6, 202637,192,632
Aug 6, 202637,181,979

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Madison Asset Management, LLC2.11M5.7%US$7.73MNo changeNov 12, 2026
Millennium1.05M2.8%US$3.87M+584KNov 16, 2026
Vanguard653K1.8%US$2.4M+173Nov 13, 2026
BlackRock558K1.5%US$2.05M−1,760Nov 13, 2026
Geode Capital279K0.75%US$1.02M+7,994Nov 6, 2026
State Street185K0.50%US$677K+54,901Nov 12, 2026
Grey Ledge Advisors, LLC100K0.27%US$367K+50,000Oct 30, 2026
Northern Trust90,5710.24%US$332K+780Nov 16, 2026
Edgewood Management LLC80,0000.22%US$294KNo changeNov 12, 2026
UBS54,3740.15%US$200K+40,677Nov 10, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Bridgeway Capital Management, LLC43,9880.12%US$161K−694Nov 16, 2026
SeaCrest Wealth Management, LLC41,8990.11%US$154K+375Oct 21, 2026
Empowered Funds, LLC40,6880.11%US$149KNewNov 13, 2026
Renaissance Technologies34,6530.09%US$127K−13,665Nov 12, 2026
BNY30,5590.08%US$112K+810Nov 5, 2026
Schwab28,8630.08%US$106K+6Nov 16, 2026
XTX Topco Ltd27,8670.07%US$102K+17,041Nov 16, 2026
Goldman Sachs25,1560.07%US$92,323NewNov 16, 2026
Hudson Bay Capital Management LP17,5840.05%US$64,533No changeNov 13, 2026
Nuveen17,5450.05%US$64,390+1,640Nov 10, 2026
Susquehanna15,9130.04%US$58,401NewNov 16, 2026
New York State Common Retirement Fund15,4000.04%US$56,518No changeNov 17, 2026
T. Rowe Price15,3300.04%US$57,000NewNov 16, 2026
Bank of America14,4840.04%US$53,156+3,179Nov 16, 2026
Nisa Investment Advisors, LLC13,6500.04%US$50,096NewOct 20, 2026
Captrust Financial Advisors13,2380.04%US$48,583+98Nov 12, 2026
DWS11,5930.03%US$42,546−373Nov 6, 2026
Dauntless Investment Group, LLC9,1050.02%US$33,415−195KNov 16, 2026
Rhumbline Advisers8,1770.02%US$30,005−276Nov 10, 2026
Police & Firemen's Retirement System of New Jersey6,0950.02%US$22,369No changeNov 9, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.5,7290.02%US$21,025+268Nov 16, 2026
JPMorgan5,6170.02%US$20,165+701Nov 12, 2026
Morgan Stanley5,4120.01%US$19,862+829Nov 13, 2026
Barclays5,1220.01%US$18,797+2,138Nov 6, 2026
Russell Investments Group, Ltd.4,5030.01%US$16,526+3,534Nov 6, 2026
Wells Fargo3,605<0.01%US$13,229−7,214Nov 16, 2026
BNP Paribas3,579<0.01%US$13,135+541Nov 12, 2026
RBC2,753<0.01%US$10,000+2,256Nov 16, 2026
Tower Research Capital LLC (TRC)2,524<0.01%US$9,263+490Nov 16, 2026
Cornerstone National Bank & Trust Co1,428<0.01%US$4,727No changeOct 20, 2026
Fidelity1,415<0.01%US$5,194+1,051Nov 10, 2026
Legal & General1,161<0.01%US$4,261No changeNov 16, 2026
Ameritas Investment Partners, Inc.1,076<0.01%US$3,949No changeNov 13, 2026
Measured Wealth Private Client Group, LLC1,000<0.01%US$3,670No changeNov 10, 2026
Trifecta Capital Advisors, LLC714<0.01%US$2,621No changeOct 21, 2026
Farther Finance Advisors, LLC597<0.01%US$2,191NewOct 8, 2026
Citigroup Inc589<0.01%US$2,162−5,014Nov 4, 2026
Northwestern Mutual Wealth Management Co571<0.01%US$2,096No changeNov 13, 2026
GAMMA Investing LLC550<0.01%US$2,019NewOct 8, 2026
Sterling Capital Management LLC389<0.01%US$1,428+347Oct 22, 2026

This page holds 50 of 61 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund350K0.94%US$2.27M+111KJun 30, 2026
iShares Russell 2000 ETF197K0.53%US$1.28MNewJun 30, 2026
Fidelity Small Cap Index Fund129K0.35%US$585KNewJul 31, 2026
Vanguard Extended Market Index Fund126K0.34%US$816K+12,275Jun 30, 2026
iShares Russell 2000 Growth ETF111K0.30%US$722KNewJun 30, 2026
Fidelity Extended Market Index Fund56,7010.15%US$463K−1,563May 31, 2026
Ultra-Small Company Market Fund41,3820.11%US$268KNo changeJun 30, 2026
iShares Micro-Cap ETF39,7430.11%US$258K+12,692Jun 30, 2026
Schwab Small-Cap Index Fund28,8570.08%US$131KNewJul 31, 2026
Master Small Cap Index Series22,1680.06%US$144KNewJun 30, 2026
All 47 holders
HolderSharesOf the companyValueChangeAs of
Fidelity Total Market Index Fund17,2960.05%US$141KNo changeMay 31, 2026
Fidelity Series Total Market Index Fund16,2710.04%US$133K+1,563May 31, 2026
Nuveen Small Cap Blend Index Fund15,9050.04%US$72,209NewJul 31, 2026
Fidelity Small Cap Growth Index Fund11,2520.03%US$72,913NewJun 30, 2026
EQ/2000 Managed Volatility Portfolio11,1640.03%US$72,343NewJun 30, 2026
LVIP State Street Small-Cap Index Fund9,7000.03%US$62,856NewJun 30, 2026
Vanguard Balanced Index Fund7,1810.02%US$46,533No changeJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio6,7000.02%US$43,416NewJun 30, 2026
Small Cap Index Fund6,1180.02%US$39,645NewJun 30, 2026
Global X Russell 2000 ETF5,6490.02%US$25,646NewJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund5,3160.01%US$34,448No changeJun 30, 2026
Small-Cap Index Portfolio3,8260.01%US$24,792NewJun 30, 2026
ATM Small Cap Managed Volatility Portfolio3,267<0.01%US$21,170NewJun 30, 2026
1290 VT Micro Cap Portfolio2,628<0.01%US$17,029+651Jun 30, 2026
NVIT Small Cap Index Fund2,478<0.01%US$16,057NewJun 30, 2026
DWS Small Cap Index VIP1,840<0.01%US$11,923NewJun 30, 2026
BlackRock Small Cap Index V.I. Fund1,796<0.01%US$11,638NewJun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio1,703<0.01%US$11,035NewJun 30, 2026
SA Small Cap Index Portfolio1,389<0.01%US$6,306NewJul 31, 2026
Victory Extended Market Index Fund1,328<0.01%US$6,029+65Jul 31, 2026
Nationwide Small Cap Index Fund1,178<0.01%US$5,348NewJul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio1,076<0.01%US$6,972NewJun 30, 2026
PD Small-Cap Growth Index Portfolio1,044<0.01%US$6,765NewJun 30, 2026
Venerable Small Cap Index Fund969<0.01%US$6,279NewJun 30, 2026
SmallCap Growth Fund I907<0.01%US$4,118NewJul 31, 2026
EQ/AB Small Cap Growth Portfolio830<0.01%US$5,378NewJun 30, 2026
EQ/Small Company Index Portfolio830<0.01%US$5,378NewJun 30, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio779<0.01%US$5,048NewJun 30, 2026
State Street Total Return V.I.S. Fund406<0.01%US$2,631NewJun 30, 2026
Ultra Small Cap Profund153<0.01%US$695NewJul 31, 2026
Russell 2000 2x Strategy Fund64<0.01%US$415NewJun 30, 2026
Profund Vp Ultra Small Cap49<0.01%US$318NewJun 30, 2026
Profund Vp Small Cap32<0.01%US$207NewJun 30, 2026
Russell 2000 Fund29<0.01%US$188NewJun 30, 2026
Russell 2000 1.5x Strategy Fund18<0.01%US$117NewJun 30, 2026
Small-Cap Profund10<0.01%US$45NewJul 31, 2026
Russell 2000(R) 1.5x Strategy Fund3<0.01%US$19NewJun 30, 2026

Big stakes

HolderStakeSharesDate
Innoviva, Inc.82.70%55.5MMay 12, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kostas D Odysseas
Other companies: Amarin Corporation plc (Director · Since at least Feb 28, 2023); Sarissa Capital Acquisition Corp (Senior Managing Director · Oct 20, 2020 – Oct 20, 2020 · Past); Innoviva, Inc. (Director · Dec 19, 2017 – Jun 17, 2024 · Past); Viskase Holdings, Inc. (Director · Sep 25, 2013 – Sep 25, 2013 · Past); Savara, Inc. (Director · Feb 2, 2010 – Jun 30, 2010 · Past)
Director · Since at least Feb 12, 2020
Louis Drapeau
Other companies: Avita Medical, Inc. (Director · Jun 30, 2020 – Dec 22, 2021 · Past); InSite Vision Inc (Vice President and CFO · Oct 28, 2008 – Nov 2, 2015 · Past); InterMune Inc (Director · Sep 6, 2007 – Sep 29, 2014 · Past); Bio-Rad Laboratories, Inc. (Director · Feb 14, 2007 – Feb 14, 2007 · Past); Nektar Therapeutics (Sr. VP Finance, CFO · Jan 17, 2006 – May 14, 2007 · Past)
Director · Feb 18, 2014 – Sep 7, 2017 · Past
H Stewart Parker
Other companies: Codexis, Inc. (Director · Since at least Dec 16, 2022); Sangamo Therapeutics, Inc. (Director · Since at least Jun 17, 2014); Impel Neuropharma Inc (Director · Apr 22, 2021 – Jul 11, 2021 · Past); Achieve Life Sciences, Inc. (Director · Mar 23, 2010 – May 12, 2020 · Past)
Director · Jun 12, 2006 – May 22, 2019 · Past
Igor Bilinsky
Other companies: Iovance Biotherapeutics, Inc. (Chief Operating Officer · Since at least Mar 15, 2021); Oncternal Therapeutics Inc (Chief Business Officer · Sep 9, 2019 – Feb 11, 2021 · Past); Vical Incorporated (Sr VP, Corporate Development · Dec 13, 2013 – Jul 13, 2015 · Past)
Chief Operating Officer · Jan 30, 2017 – May 30, 2017 · Past
Paul C Grint
Other companies: Inhibikase Therapeutics, Inc. (Director · Dec 22, 2020 – Jul 16, 2024 · Past); Regulus Therapeutics Inc (President & CEO, Director · Jun 16, 2014 – Feb 15, 2017 · Past); Illumina, Inc. (Director · Jun 8, 2006 – Jan 3, 2013 · Past)
Chief Executive Officer, Director · Nov 5, 2015 – Dec 8, 2017 · Past
Robin Kramer
Other companies: Biogen Inc. (Chief Financial Officer · Since at least Nov 19, 2018); Hertz Global Holdings, Inc (Sr VP Chief Accounting Officer · Jun 6, 2016 – Apr 29, 2018 · Past); Herc Holdings Inc. (Sr VP, ChiefAccountingOfficer · May 16, 2014 – May 15, 2016 · Past)
Chair of Board of Directors · Since at least Dec 8, 2020
Sarah J. Schlesinger
Other companies: Innoviva, Inc. (Board Member · Since at least Feb 12, 2018); The Medicines Company (Director · Feb 22, 2018 – Jan 6, 2020 · Past); Ariad Pharmaceuticals Inc (Director · Jul 15, 2013 – Feb 13, 2017 · Past)
Director · Since at least Feb 12, 2020
Vijay B Samant
Other companies: Brickell Biotech Inc (Director · Feb 14, 2020 – May 17, 2022 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Apr 7, 2014 · Past); Vical Incorporated (President & CEO, Director · Apr 6, 2007 – Jun 18, 2018 · Past)
Director · Nov 5, 2015 – Sep 7, 2017 · Past
Jack L Bowman
Other companies: Sarepta Therapeutics, Inc. (Director · Mar 17, 2006 – May 22, 2007 · Past); Celgene Corporation (Director · Feb 2, 2006 – Sep 17, 2007 · Past)
Director · May 8, 2006 – May 17, 2007 · Past
Jeremy Curnock Cook
Other companies: Avita Medical, Inc. (Director · Since at least Jun 30, 2020); Sirna Therapeutics Inc (Director · Jun 14, 2006 – Dec 29, 2006 · Past)
Director · May 8, 2006 – Dec 31, 2019 · Past
All 41 people
PersonSeat
Joseph Md Phd Davie
Other companies: Curis, Inc. (Director · Jan 25, 2008 – Jan 7, 2011 · Past); CV Therapeutics Inc (Director · Jan 13, 2006 – Apr 14, 2009 · Past)
Director · May 8, 2006 – May 29, 2009 · Past
Joseph M. Patti
Other companies: Vaxart, Inc. (CEO, Director · Nov 12, 2012 – Apr 3, 2017 · Past); Inhibitex Inc (Chief Scientific Officer · Jan 10, 2006 – Feb 13, 2012 · Past)
Director · Since at least May 9, 2019
Michael Perry
Other companies: Arrowhead Pharmaceuticals, Inc. (Director · Since at least Dec 22, 2011); Avita Medical, Inc. (Director · Sep 14, 2019 – Nov 21, 2022 · Past)
Director · May 8, 2006 – Dec 31, 2019 · Past
Philip J Young
Other companies: Panacea Life Sciences Holdings Inc (PRESIDENT AND CEO, Director · Aug 18, 2017 – Sep 4, 2018 · Past); Insmed Incorporated (CBO and EVP, Commercial Ops · Dec 31, 2005 – Dec 31, 2006 · Past)
President and CEO, Director · Feb 18, 2014 – Feb 18, 2014 · Past
Wendy S Johnson
Other companies: OnKure Therapeutics, Inc. (Chief Development Officer · Apr 8, 2021 – Jul 14, 2021 · Past); Exagen Inc. (Director · Oct 1, 2020 – Jun 9, 2023 · Past)
Director · Sep 8, 2015 – Sep 7, 2017 · Past
Deborah Birx
Other companies: Innoviva, Inc. (Director · Mar 9, 2021 – May 22, 2023 · Past)
Chief Executive Officer · Since at least Jul 10, 2023
Erin Butler
Other companies: ImageneBio, Inc. (Principal Accounting Officer · Since at least Jul 25, 2025)
Vice President,Finance & Admin · Jul 1, 2022 – Jul 1, 2022 · Past
Jules Haimovitz
Other companies: Innoviva, Inc. (Chairman of the Board · Since at least Feb 12, 2018)
Director · Since at least Apr 1, 2021
Julianne Averill
Other companies: Biomea Fusion, Inc. (Director · Since at least Jul 22, 2025)
Chief Financial Officer · May 2, 2023 – May 2, 2023 · Past
Julian P Kirk
Other companies: Fibrocell Science Inc (Director · Oct 9, 2012 – Dec 13, 2019 · Past)
Director · Feb 18, 2014 – Sep 21, 2015 · Past
Kelley A Wendt
Other companies: Panacea Life Sciences Holdings Inc (CHIEF FIN OFFICER AND TREAS · Aug 18, 2017 – Sep 4, 2018 · Past)
Chief Financial Officer · Feb 18, 2014 – Feb 18, 2014 · Past
Louis P Lacasse
Other companies: Histogen Inc (Director · Jul 24, 2013 – Jun 11, 2015 · Past)
Director · May 8, 2006 – May 8, 2006 · Past
Michael Scott Salka
Other companies: Sorrento Therapeutics, Inc. (Director · Feb 23, 2012 – Jan 23, 2014 · Past)
Chief Executive Officer, Director · Aug 5, 2015 – Apr 1, 2017 · Past
Odysseas Kostas
Other companies: Amarin Corporation plc (Non-Executive Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Richard Bastiani
Other companies: Abaxis Inc (Director · Apr 25, 2006 – Jul 31, 2018 · Past)
Director · May 9, 2019 – Dec 8, 2020 · Past
Richard Bear
Other companies: CRH Medical Corporation (Chief Financial Officer · Jan 1, 2019 – Apr 22, 2021 · Past)
Director · May 9, 2019 – May 22, 2019 · Past
Steve Martin
Other companies: Ensysce Biosciences, Inc. (Director · Since at least Jun 30, 2021)
Chief Financial Officer · Dec 9, 2016 – Mar 25, 2021 · Past
Todd Patrick
Other companies: CRH Medical Corporation (Director · Jan 1, 2019 – Apr 22, 2021 · Past)
Director · May 9, 2019 – Apr 13, 2022 · Past
Bani TchekanovaHead of Regulatory Strategy and Operations · Since at least Nov 5, 2026
Barrie J Phd CarterExecutive Vice President · Jun 12, 2006 – May 15, 2008 · Past
BG Susan RobinsonPresident and CEO, Director · Nov 6, 2008 – Apr 16, 2010 · Past
Brian VarnumPresident and CEO · May 9, 2019 – Apr 13, 2022 · Past
Daniel B. GilmerDirector · Since at least Apr 24, 2026
David HouseChief Financial Officer · Since at least Aug 16, 2024
David J PostonVice President and CFO · Jun 12, 2006 – Apr 16, 2010 · Past
Duane Alfred MorrisVP of Operations · May 9, 2019 – Apr 13, 2022 · Past
Nelson L LevyDirector · May 8, 2006 – May 29, 2009 · Past
Peter HubbardVice President of Operations · Since at least Nov 4, 2026
Pierre KymeChief Business Officer · Since at least Jun 19, 2024
Richard RychlikCorporate Controller and PFO · Sep 15, 2023 – Mar 14, 2024 · Past
Todd C PetersonDirector · Since at least Oct 10, 2019

Open People

Log in to ask 6ix AI your own questions about Armata Pharmaceuticals, Inc.